BiotechTube

HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Conditions

Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Trial Timeline

Sep 25, 2024 → Nov 1, 2025

NCT ID
NCT06569056

About HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo

HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06569056. Target conditions include Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP).

What happened to similar drugs?

4 of 20 similar drugs in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) were approved

Approved (4) Terminated (3) Active (15)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Co-artemetherNovartisApproved
🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
🔄CXA-201 and metronidazole + MeropenemMerckPhase 3
🔄Imipenem+Cilastatin/RelebactamMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06569056Phase 3Recruiting

Competing Products

20 competing products in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
31
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
CXA-101 + CeftazidimeMerckPhase 2
35
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
35
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
Daptomycin + VancomycinMerckApproved
35
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
CXA-201 + LevofloxacinMerckPhase 3
40
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
KLU156 + CoartemNovartisPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35